Timed Temozolomide Treatment in Glioblastoma Patients: A Retrospective Study

Patients taking morning temozolomide experienced a longer median overall survival of 1.43 years compared to 1.13 years for those taking it in the evening.

• Morning administration of temozolomide is associated with improved overall survival in glioblastoma patients.
• The difference in median overall survival suggests a potential benefit of timing in treatment delivery.
• Among patients with MGMT-methylated tumors, morning treatment resulted in a median overall survival increase of 6 months.
• Significant survival differences favoring morning administration were observed at years 1, 2, and 5.
• Preliminary findings indicate that chronotherapy may enhance treatment outcomes for glioblastoma patients, particularly those with specific genetic markers.

Simplified